Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid CancerAlan L. Ho, James A. Fagin, Ravinder K. Grewal et al.|New England Journal of Medicine|2013Cited by 825
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and SurvivalGiulia Polverari, Désirèe Deandreis, Andrea Veltri et al.|Cancers|2020Cited by 97
68Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC): a prospective single-centre study in patients eligible for salvage therapyDésirèe Deandreis, Paolo Gontero, Alessia Guarneri et al.|European Journal of Nuclear Medicine and Molecular Imaging|2020Cited by 39
Event-free survival after 68 Ga-PSMA-11 PET/CT in recurrent hormone-sensitive prostate cancer (HSPC) patients eligible for salvage therapyFrancesco Ceci, Désirèe Deandreis, Guido Rovera et al.|European Journal of Nuclear Medicine and Molecular Imaging|2022Cited by 26
Predictive factors of a worse response to radioactive Iodine-I131 treatment in hyperthyroidism: outcome analysis in 424 patients. A single centre experienceMonica Finessi, Désirèe Deandreis, Alessandro Bisceglia et al.|Endocrine|2021Cited by 15